While earlier today we profiled how the penny stock of Eternity Healthcare, Inc. (ETAH) surged of early morning news, another biotech player which just recently began to trade had an even better showing off of a midday announcement. Regen BioPharma, Inc. (RGBP), a subsidiary of Bio-Matrix Scientific Group, Inc. (BMSN), made it known just before noon EST today that the biotechnology company filed a patent application covering novel means of stimulating the “innate” immune system to kill cancer. The news was enough to send stock skyrocketing for better than 200% gains even though their parent’s ticker, BMSN stock, barely even budged despite this apparent “new approach” supposedly appears to be effective against various human cancers including lung, skin, glioma, and breast cancer.
Want to crush the Markets and make profits of $624, $2,897, even $40,656?
Click HERE To Make Sure You Don’t Miss Our Penny Stock Alerts!
RGBP Stock Quote
Market Cap: 15.05M
Last: 0.29 ▲ +0.155 (+114.81%)
Dollar Volume: $149,926
14-Day RSI: N/A
1st Resistance Point: 0.379
1st Support Level: 0.152
52Wk High: 1.00
52Wk Low: 0.01
Regen BioPharma is about as fresh of a biotech company as one can stumble across, having not only just recently begun trading RGBP stock, but having just filed their S1 less than a year ago. From their most recent Q filing for the period ended June 30, 2014, the Company had $49,395 and nearly equal liabilities, $57,460, $50,000 was loaned to them by Bio Matrix Solutions and bears a simple interest at a rate of 10% per annum.
So with the limited financial capabilities Regen BioPharma appears to have on paper, the Company filed for a patent patent which discloses specific siRNA molecules that were discovered by them during the preclinical development of dCellVax. The keyword is “preclinical”, not “patent” for those who read between the lines correctly as it clearly demonstrates that, although a spinoff/start up from Bio Matrix, RGBP stock is one which deserves to be paid attention to for reasons beyond today’s PR.
Interestingly, David R. Koos, the sole officer and director of Bio Matrix Scientific Group, owned 50,010,000 shares of RGBP stock at the time of the S1 filing, October, 2013. A month prior, 100,000 shares were issued to ASC Recap, LLC for consideration of $100,000, $1 a friggin share, while 1,500,000 shares belonged to Caven Investments LLC, owned by Todd S. Caven, which they received for the satisfaction of $70,000 of the outstanding indebtedness owed to them by Bio-Matrix, $0.0466 per share. So with just 51,907,917 shares of RGBP stock issued and outstanding as of August 2, 2014, it’s no wonder why news of a patent filing was able to send the share price into orbit since the float is less than 2,000,000.
Looking for the Best Penny Stocks to Buy?
Click HERE To Receive FREE Penny Stock Alerts
About RGBP Stock
Regen BioPharma, Inc., a wholly owned subsidiary of Bio-Matrix Scientific Group, Inc., is a development stage company that intends to engage primarily in the development of regenerative medical applications which the company plans to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which the intent would be to either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials.
Issued and Outstanding: 51,907,917
Last 5 Trading Sessions:
RGBP proved today why it needs to be on everyone’s list of penny stocks to watch. While it has a much better share structure than other biotech runners of the past, Amarantus Bioscience Holdings, Inc (AMBS) and OncoSec Medical Incorporated (ONCS), RGBP stock is one which might do what AMBS stock and ONCS stock failed to do – break past $1.
(We are 100% Anti-Spam and will never rent or sell your information) Although many of our picks go up 100, 200% even 4,000%, there is always the chance a stock could move lower.
Please read and understand our rules very carefully:
1. Penny Stocks can be very dangerous, unless you understand the risk involved with them do not try to trade them. Many go up fast and can drop just as fast;
2. Do not risk too much in one company. You can lose it all very quickly;
3. Do not “marry” any one stock. Recognize if you are wrong about a stock, cut your losses and move on to the next stock; and
4. Always use stop loss orders. We recommend that you use “trailing stops” in order to protect your profits.